Pneumonia - Bacterial
92
10
13
55
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
15 trials with published results (16%)
Research Maturity
55 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.3%
4 terminated out of 92 trials
93.2%
+6.6% vs benchmark
15%
14 trials in Phase 3/4
27%
15 of 55 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 55 completed trials
Clinical Trials (92)
Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections
Discharge Stewardship in Children's Hospitals
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)
Urine Pneumococcal Antigen Project
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy
" Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation "
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
Systematic Search for Primary Immunodeficiency in Adults With Infections
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.